About SilverCloud by Amwell
SilverCloud by Amwell delivers the national digital guided CBT service on behalf of the HSE, having seen over 42k referrals and 24k patient activations in the past 3 years for mild-to-moderate levels of depression and anexity.
SilverCloud by Amwell® (NYSE: AMWL) is a leading digital mental health platform, enabling providers, health plans and employers to deliver clinically validated digital health/therapeutic care that improves outcomes and increases access and scale while reducing costs. Developed in Ireland in 2012, the multi-award-winning digital mental health platform is a result of nearly 20 years of clinical research with leading academic institutions.
Today, SilverCloud is being used by more than 500 organizations globally to meet their populations’ mental health needs. Global experts have clinically proven the platform through fully randomized control trials and anonymized, real-world data from over one million SilverCloud users. The platform is a leader in the industry with its effectiveness, engagement and range of clinical programs that encompasses the spectrum of mental health needs.
SilverCloud programs are designed to break down barriers and empower lives – using internet-based Cognitive Behavioural Therapy (iCBT). Our programs educate participants to better understand their thoughts, feelings, and behaviours and learn how to make positive changes – proven to reduce symptoms and better manage their mental health and wellbeing. SilverCloud programs are designed to support the Stepped Care model by providing patients with the right level of care and support. Using SilverCloud programs, patients are able to utilize digital programs and tools as a self-management tool, while they are waiting for care, between visits, and post treatment to maintain recovery.
Outcomes are SilverCloud’s North Star, with our Digital Health Science Team at the forefront of scientific excellence and evidence generation: 56% of users with a clinical diagnosis of depression or anxiety were diagnosis free at 3 months, sustainable results with a 50% further decrease in symptoms scores at 12 months, and up to 80% of users show improvement in depression and anxiety symptoms, and 65% of users experience clinically significant improvement.
